Nosocomial Infection Clinical Trial
Official title:
Achromobacter Xylosoxidans Infections : Epidemiology and Environmental Investigations
Data extraction from bacteriological laboratory of Martinique University hospital to determine the frequency and the distribution of nosocomial infections due to Achromobacter xylosoxidans (ACHX), an emerging multi-resistant environmental bacteria. The specific tropical environment and climatic conditions in Martinique may favor ACHX development and the investigators suppose that this new opportunistic pathogen can represent a danger for hospitalized patients. The aim of our study is to describe the most affected population and try to identify the main environmental sources of contamination.
In June 2016, a patient who developed a Staphylococcus aureus mediastinitis died of a
superinfection by Achromobacter xylosoxidans. This germ is an hydrotelluric bacteria
described as emergent and multi-resistant, involved in nosocomial infections. It is known to
be responsible for severe nosocomial infections in immunocompromised individuals
(endocarditis, bacteriemia, wound infections, pneumonia) associated with high morbidity and
mortality but it is also able to infect immunocompetent patients. According to literature, it
is capable of developing in antiseptic and disinfectant solutions due to the acquisition of
resistance to these products. Moreover it has a great ability to form biofilms, resulting in
major eradication difficulties, both on the environmental and clinical level.
Various environmental sources of contamination have been identified, including dental units
water lines, dialysis water, nebulizers, reusable boxes of disinfectant wipes, siphons of
patient's rooms, vials of heparin...
There is no evidence for the existence of a possible portage in humans, but ACHX has already
been isolated from the intestine of a 3-month-old baby who has never received antibiotic
treatment. On the other hand, this germ colonizes the respiratory system of patients with
cystic fibrosis. The frequency of isolation in sputum of these patients is increasing for a
decade for still unknown reasons. ACHX surgical site infections are rare and to our knowledge
only two cases of ACHX mediastinitis have been reported in the literature to date, either
because cases are indeed rare or because the high mortality rate restricts publications. The
clinical case of our CHU caught our attention and the investigators contacted the laboratory
of bacteriology to inquire about the existence of other cases of infection with this germ.
The investigators have then seen that ACHX seems to evolve in low noise for more than 10
years in our hospital with about 10 cases of infection per year.
Also, the investigators wanted to learn more and propose a study articulated around two axes:
- An epidemiological axis, in which the investigators detail local epidemiology, calculate
rates of impact and analyze their evolution over 10 years, identify the most affected
units, identify the types of most common infections, identify a population at risk,
study profiles of resistance of the isolated strains,
- An environmental axis with identification of potential sources after development of
appropriate analytical methods.
The ultimate goal of this study is the protection of patients by the fight against ACHX
nosocomial infections and other related germs, by preventive eradication methods of
environmental sources once they have been identified. The investigators want to avoid a new
fatal infection episode.
A research of ACHX natural reservoirs in Martinique is also conceivable subsequently, the
hypothesis being that this germ, particularly greedy of heat and humidity, is very present in
a tropical environment.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03365635 -
Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C
|
Phase 4 | |
Recruiting |
NCT05904535 -
Novel Diagnostic Methods to Identify External Ventricular Drain Associated Infections
|
||
Completed |
NCT01704430 -
Glutamine to Improve Outcomes in Cardiac Surgery
|
N/A | |
Terminated |
NCT01225159 -
Tight Glycaemic Control During Cardiac Surgery
|
N/A | |
Recruiting |
NCT04659356 -
NOSOcomial COVID-19 in ICU (NOSOCOVID)
|
||
Terminated |
NCT03423147 -
Preoperative Application of Chlorhexidine to Reduce Infection With Cesarean Section After Labor
|
Phase 2 | |
Recruiting |
NCT04252651 -
Association of Cytokines With the Development of Complications in Burn and Toxic Epidermal Necrolysis (TENS) Patients
|
||
Completed |
NCT04405934 -
COG-UK Project Hospital-Onset COVID-19 Infections Study
|
N/A | |
Active, not recruiting |
NCT03865706 -
Inulin for Infections in the Intensive Care Unit
|
Phase 2 | |
Recruiting |
NCT05411562 -
COVID-19 Genomic Sequencing for Nosocomial Outbreak Investigations
|
||
Completed |
NCT03250104 -
Antibiotic Stewardship and Infection Control in Patients at High Risk of Developing Infection by Clostridium Difficile, Vancomycin-Resistant Enterococci or Multi-Resistant Gram-Negatives
|
||
Completed |
NCT00864929 -
An Epidemiological Study on Antimicrobial Treatment of Nosocomial Infections in Clinical Practice
|
N/A | |
Completed |
NCT01763008 -
A Study of the Safety and Effectiveness of Doripenem in Filipino Patients With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections
|
Phase 4 | |
Terminated |
NCT01515020 -
Daptomycin Versus Vancomycin in the Treatment of Nosocomial or Healthcare-associated MRSA Bacteremia
|
Phase 3 | |
Active, not recruiting |
NCT05511129 -
Tolerance and Efficacy of Amiklin Administration During Nosocomial Infections Complicating COVID-19 in the ICU
|
||
Completed |
NCT04212130 -
Can Environmental Cleanliness be Assessed by BCA (Bicinchoninic Acid) Method
|
N/A | |
Active, not recruiting |
NCT05988853 -
Biosafety of Musical Instruments in the ICU
|
||
Recruiting |
NCT01943331 -
Epidemiological Investigation of CRBSI, VAP, CAUTI in Chinese ICU
|
N/A | |
Completed |
NCT00105625 -
VA Nutrition Study on Immune Function
|
N/A | |
Not yet recruiting |
NCT03857295 -
Infections Following NeuroSurgery (INS)
|